|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 262.80 ILa | +0.73% |
|
-12.22% | -18.79% |
| 04-30 | InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 03-03 | InterCure Receives Noncompliance Notice From Nasdaq | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 (ILS) | 2019 (ILS) | 2020 (ILS) | 2021 (ILS) | 2022 (ILS) | 2023 (ILS) | 2024 (ILS) | 2025 (ILS) |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.75 | 3.09 | -0.11 | -7.09 | -5.78 | |||||
Return on Total Capital | 4.39 | 3.77 | -0.13 | -8.71 | -7.07 | |||||
Return On Equity % | 1.94 | 8.83 | -12.99 | -17.03 | -9.27 | |||||
Return on Common Equity | 1.3 | 9.44 | -12.96 | -15.91 | -9 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 46.69 | 44.25 | 30.54 | 17.61 | 15.06 | |||||
SG&A Margin | 22.95 | 23.83 | 26.97 | 45.17 | 34.57 | |||||
EBITDA Margin % | 16.17 | 12.44 | 1.88 | -32.75 | -20.48 | |||||
EBITA Margin % | 13.84 | 10.51 | -0.42 | -36.8 | -24.89 | |||||
EBIT Margin % | 13.84 | 10.51 | -0.42 | -36.8 | -24.89 | |||||
Income From Continuing Operations Margin % | 3.32 | 11.26 | -17.87 | -30.48 | -13.61 | |||||
Net Income Margin % | 2.14 | 11.53 | -17.43 | -28.38 | -13.22 | |||||
Net Avail. For Common Margin % | 2.14 | 11.53 | -17.43 | -28.38 | -13.22 | |||||
Normalized Net Income Margin | 4.78 | 5.75 | -3.29 | -26.17 | -18.99 | |||||
Levered Free Cash Flow Margin | 3.31 | -12.02 | -16.41 | -13.06 | -13.85 | |||||
Unlevered Free Cash Flow Margin | 3.43 | -11.92 | -16.28 | -7.66 | -9.31 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.43 | 0.47 | 0.41 | 0.31 | 0.37 | |||||
Fixed Assets Turnover | 3.14 | 4.1 | 3.54 | 2.36 | 2.6 | |||||
Receivables Turnover (Average Receivables) | 14.15 | 13.1 | 6.98 | 4.21 | 7.28 | |||||
Inventory Turnover (Average Inventory) | 2.88 | 2.38 | 2.01 | 1.74 | 2.01 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.74 | 1.62 | 1.85 | 1.73 | 1.48 | |||||
Quick Ratio | 1.19 | 0.95 | 1.03 | 0.96 | 0.91 | |||||
Operating Cash Flow to Current Liabilities | 0.13 | 0.16 | -0.24 | -0.3 | 0.08 | |||||
Days Sales Outstanding (Average Receivables) | 25.8 | 27.87 | 52.29 | 87.02 | 50.14 | |||||
Days Outstanding Inventory (Average Inventory) | 126.79 | 153.67 | 181.5 | 209.95 | 181.56 | |||||
Average Days Payable Outstanding | 94.56 | 126.68 | 175.81 | 134.88 | 122.41 | |||||
Cash Conversion Cycle (Average Days) | 58.04 | 54.86 | 57.99 | 162.09 | 109.29 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 23.72 | 48.93 | 42.81 | 53.16 | 46.17 | |||||
Total Debt / Total Capital | 19.17 | 32.85 | 29.98 | 34.71 | 31.59 | |||||
LT Debt/Equity | 7.26 | 23.55 | 22.5 | 34.5 | 19.92 | |||||
Long-Term Debt / Total Capital | 5.87 | 15.81 | 15.76 | 22.52 | 13.63 | |||||
Total Liabilities / Total Assets | 33.09 | 45.57 | 41.9 | 47.85 | 42.6 | |||||
EBIT / Interest Expense | 72.75 | 64.85 | -2.07 | -4.26 | -3.42 | |||||
EBITDA / Interest Expense | 90.44 | 83.42 | 16.06 | -3.51 | -2.55 | |||||
(EBITDA - Capex) / Interest Expense | 56.88 | 52.08 | 12.46 | -3.72 | -2.73 | |||||
Total Debt / EBITDA | 2.88 | 4.86 | 16.78 | -2.92 | -3.65 | |||||
Net Debt / EBITDA | -2.32 | 0.43 | 8.09 | -1.83 | -2.72 | |||||
Total Debt / (EBITDA - Capex) | 4.58 | 7.78 | 21.64 | -2.75 | -3.41 | |||||
Net Debt / (EBITDA - Capex) | -3.69 | 0.68 | 10.43 | -1.73 | -2.54 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 237.78 | 76.93 | -8.52 | -32.82 | 13.13 | |||||
Gross Profit, 1 Yr. Growth % | 205.36 | 67.71 | -36.86 | -61.28 | -3.21 | |||||
EBITDA, 1 Yr. Growth % | 2.39K | 36.06 | -86.18 | -1.04K | -29.25 | |||||
EBITA, 1 Yr. Growth % | -2.62K | 34.35 | -103.68 | -83.8K | -23.49 | |||||
EBIT, 1 Yr. Growth % | -2.62K | 34.35 | -103.68 | -83.8K | -23.49 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -120.24 | 499.88 | -245.22 | 14.58 | -49.47 | |||||
Net Income, 1 Yr. Growth % | -112.6 | 855.63 | -238.24 | 9.42 | -47.33 | |||||
Normalized Net Income, 1 Yr. Growth % | -656.39 | 113.07 | -152.27 | 485.02 | -17.92 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -106.82 | 798.39 | -237.62 | 8.82 | -55.1 | |||||
Accounts Receivable, 1 Yr. Growth % | 49.16 | 119.21 | 49.96 | -14.18 | -58.47 | |||||
Inventory, 1 Yr. Growth % | 227.12 | 92.79 | -24.74 | 14.07 | -10.22 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 61.79 | 19.22 | -5.49 | 7.97 | -2.31 | |||||
Total Assets, 1 Yr. Growth % | 110.35 | 37.54 | -17.89 | -3.06 | -9.44 | |||||
Tangible Book Value, 1 Yr. Growth % | 125.06 | 20.8 | 7.79 | -26.35 | 2.87 | |||||
Common Equity, 1 Yr. Growth % | 63.21 | 11.89 | -9.21 | -12.78 | -0.11 | |||||
Cash From Operations, 1 Yr. Growth % | 220.65 | 70.12 | -204.61 | 24.79 | -125.16 | |||||
Capital Expenditures, 1 Yr. Growth % | -32.69 | 40.73 | -86.73 | 67.09 | -18.9 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -156.3 | -742.36 | -12.57 | -56.7 | 20.02 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -159.07 | -714.87 | -12.74 | -67.86 | 37.52 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 396.09 | 144.47 | 27.22 | -21.61 | -12.83 | |||||
Gross Profit, 2 Yr. CAGR % | 374.99 | 126.3 | 2.9 | -50.56 | -38.78 | |||||
EBITDA, 2 Yr. CAGR % | -34.2 | 385.81 | -57.76 | 22.73 | 104.21 | |||||
EBITA, 2 Yr. CAGR % | -39.43 | 482.27 | -77.64 | 47.81 | 2.43K | |||||
EBIT, 2 Yr. CAGR % | -39.43 | 482.27 | -77.64 | 47.81 | 2.43K | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 11.26 | 10.18 | 195.15 | 28.99 | -23.91 | |||||
Net Income, 2 Yr. CAGR % | -10.77 | 9.72 | 263.47 | 22.99 | -24.08 | |||||
Normalized Net Income, 2 Yr. CAGR % | -55.9 | 244.29 | 6.67 | 68.66 | 119.13 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -37.12 | -17.9 | 251.62 | 22.38 | -30.1 | |||||
Accounts Receivable, 2 Yr. CAGR % | 242.29 | 80.82 | 81.31 | 13.44 | -40.3 | |||||
Inventory, 2 Yr. CAGR % | 266.27 | 151.13 | 30.1 | -7.34 | 1.2 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 64.04 | 38.88 | 6.15 | 1.02 | 2.7 | |||||
Total Assets, 2 Yr. CAGR % | 55.94 | 71.35 | 6.27 | -10.78 | -6.3 | |||||
Tangible Book Value, 2 Yr. CAGR % | 46.92 | 60.39 | 14.11 | -10.9 | -12.95 | |||||
Common Equity, 2 Yr. CAGR % | 32.3 | 35.14 | 0.79 | -11.01 | -6.66 | |||||
Cash From Operations, 2 Yr. CAGR % | 47.06 | 154.81 | 33.41 | 14.26 | -43.96 | |||||
Capital Expenditures, 2 Yr. CAGR % | -29.4 | -2.67 | -56.79 | -52.92 | 16.41 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -40.17 | 90.17 | 187.62 | -35.9 | -27.91 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -37.3 | 90.59 | 181.33 | -47.66 | -33.52 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | - | 251.81 | 76.16 | 2.83 | -11.41 | |||||
Gross Profit, 3 Yr. CAGR % | - | 235.72 | 47.87 | -25.71 | -38.15 | |||||
EBITDA, 3 Yr. CAGR % | 51.96 | -16.17 | 48.31 | 27.83 | 2.15 | |||||
EBITA, 3 Yr. CAGR % | 44.24 | -21.01 | 7.64 | 43 | 18.68 | |||||
EBIT, 3 Yr. CAGR % | 44.24 | -21.01 | 7.64 | 43 | 18.68 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -17.09 | 95.08 | 20.8 | 115.31 | -5.62 | |||||
Net Income, 3 Yr. CAGR % | -28.43 | 96.66 | 18.5 | 143.6 | -7.29 | |||||
Normalized Net Income, 3 Yr. CAGR % | 11.18 | -25.45 | 83.67 | 82.56 | 32.66 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -48.03 | 57.5 | -2.47 | 137.84 | -12.39 | |||||
Accounts Receivable, 3 Yr. CAGR % | - | 195.04 | 69.89 | 41.3 | -18.85 | |||||
Inventory, 3 Yr. CAGR % | - | 195.73 | 76.91 | 24.52 | -8.31 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 901.97 | 47.48 | 22.16 | 6.75 | -0.1 | |||||
Total Assets, 3 Yr. CAGR % | 167.34 | 50.29 | 34.09 | 3.06 | -10.34 | |||||
Tangible Book Value, 3 Yr. CAGR % | 112.98 | 35.12 | 40.49 | -1.38 | -6.53 | |||||
Common Equity, 3 Yr. CAGR % | 183.5 | 25.11 | 18.36 | -3.95 | -7.52 | |||||
Cash From Operations, 3 Yr. CAGR % | 156.3 | 64.25 | 89.38 | 30.47 | -31 | |||||
Capital Expenditures, 3 Yr. CAGR % | 432.33 | -11.15 | -49.91 | -32.18 | -43.56 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 40.04 | 32 | 65.28 | 64.14 | -21 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 31.82 | 34.21 | 65.56 | 35.72 | -27.77 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 92.97 | 32.96 | |||||
Gross Profit, 5 Yr. CAGR % | - | - | - | 56.04 | 3.92 | |||||
EBITDA, 5 Yr. CAGR % | - | 111.39 | -7.98 | -0.95 | 93.35 | |||||
EBITA, 5 Yr. CAGR % | 98.82 | 104.26 | -31.73 | 1.18 | 123.53 | |||||
EBIT, 5 Yr. CAGR % | 98.82 | 104.26 | -31.73 | 1.18 | 123.53 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 96.19 | 51.28 | 37.78 | 65.33 | 0.41 | |||||
Net Income, 5 Yr. CAGR % | 79.61 | 52.02 | 37.09 | 62.99 | -0.83 | |||||
Normalized Net Income, 5 Yr. CAGR % | 68.54 | 71.67 | 8.88 | 2.98 | 93.59 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 41.23 | 24.6 | 13.8 | 42.38 | -14.64 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | - | - | 101.3 | 11.81 | |||||
Inventory, 5 Yr. CAGR % | - | - | - | 91.72 | 41.49 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 545.86 | 662.55 | 308.2 | 26.77 | 13.97 | |||||
Total Assets, 5 Yr. CAGR % | 89.96 | 107.1 | 85.39 | 21.99 | 16.18 | |||||
Tangible Book Value, 5 Yr. CAGR % | 51.15 | 58.48 | 64.11 | 14.39 | 16.01 | |||||
Common Equity, 5 Yr. CAGR % | 79.44 | 87.35 | 87.46 | 9.17 | 7.63 | |||||
Cash From Operations, 5 Yr. CAGR % | 86.46 | 121.3 | 104.87 | 42.06 | 16.36 | |||||
Capital Expenditures, 5 Yr. CAGR % | 357.49 | - | 94.95 | -31.08 | -29.82 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 117.83 | 86.57 | 85.6 | 8.95 | 23.7 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 139.29 | 94.92 | 77.45 | -0.94 | 14.53 |
- Stock Market
- Stocks
- INCR Stock
- Financials InterCure Ltd.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















